Application
TNFRSF10A Antibody (C-term) western blot analysis in NCI-H292 cell line lysates (35ug/lane).This demonstrates the TNFRSF10A antibody detected the TNFRSF10A protein (arrow).| Product Name | TNFRSF10A Antibody (C-term) |
|---|---|
| Antibody Type | Primary Antibodies |
| Clonality | Polyclonal |
|---|---|
| Isotype | Ig |
| Host Species | Rabbit |
| Tested Applications | WB |
| WB:1:100~500 |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Gene Synonyms | APO2, DR4, TRAILR1 |
|---|---|
| Alternative Names | TNFRSF10A APO2 DR4 TRAILR1 Tumor necrosis factor receptor superfamily member 10A Death receptor 4 TNF-related apoptosis-inducing ligand receptor 1 CD_antigen=CD261 Flags: Precursor |
| Molecular Weight(MW) | 50089 Da |
| Function | Receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF- kappa-B |
| Tissue Specificity | Widely expressed. High levels are found in spleen, peripheral blood leukocytes, small intestine and thymus, but also in K-562 erythroleukemia cells, MCF-7 breast carcinoma cells and activated T-cells |
| Cellular Localization | Membrane; Single-pass type I membrane protein |
| Entrez Gene | 8797 |
|---|---|
| Nucleotide Accession | NP_003835.3 |
Application
TNFRSF10A Antibody (C-term) western blot analysis in NCI-H292 cell line lysates (35ug/lane).This demonstrates the TNFRSF10A antibody detected the TNFRSF10A protein (arrow).| Application Notes | WB:1:100~500 |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
